Tuesday, 18 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com

AFFLUENT MEDICAL Stock 14.38% Up Today

Loading stream...

(vianews) - the market ended the session with affluent medical (afme.pa) rising 14.38% to €1.83 on tuesday while cac 40 rose 0.84% to €8,087.48.

affluent medical's last close was €1.60, 30.43% under its 52-week high of €2.30.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -40.37%.

volatility

affluent medical's last week, last month's, and last quarter's current intraday variation average was 1.31%, 0.17%, and 4.42%.

affluent medical's highest amplitude of average volatility was 2.87% (last week), 5.22% (last month), and 4.42% (last quarter).

moving average

affluent medical's worth is way higher than its 50-day moving average of €1.31 and way above its 200-day moving average of €1.23.

more news about affluent medical (afme.pa).